Johns Hopkins
Liver Cancer Detection Score Developed With Machine Learning Analysis of Blood Plasma DNA Fragments
Researchers used machine learning to come up with a cell-free DNA 'fragmentome'-based score for finding hepatocellular carcinoma cases from blood plasma samples.
The company is aiming to launch clinical testing services by the second half of next year, using a high-sensitivity, patient-personalized assay technology.
Liquid Biopsy Startup Haystack Oncology Raises $56M in Series A Round
The company was spun out of Johns Hopkins last year to commercialize a circulating tumor DNA-detection technology for minimal residual disease testing.
Researchers reported prospective randomized trial data showing non-inferiority of adjuvant treatment guided by minimal residual disease testing.
The company aims to release an initial tissue-based prognostic this year, with a less-invasive sponge-sampling version for screening high-risk individuals to follow in 2023.